Mike deMilt advises life science clients on pricing and payer access strategy, early asset and pipeline strategy, understanding impacts of evolving market dynamics such as the Inflation Reduction Act (IRA) on development, commercialization, and access strategies.
At Avalere, Mike has supported clients develop launch pricing and contracting strategies, refine payer positioning, impact modeling evaluating commercial opportunity and risk mitigation, and guide go/no-go decisions related to indication sequencing, early asset development, access, pricing and reimbursement. He has experience supporting clients with assets spanning all phases of development across multiple therapeutic areas.
Prior to joining Avalere, Mike was a vice president at Destum Partners, a boutique biopharma and life science consulting and transaction advisory firm where he led strategic engagements (market and financial analytics) and supported advisory mandates (buy-side and sell-side transactions) for US, EU, and global clients. Prior to that, Mike was a product specialist with the biotechnology company Tetracore, where he supported the development of innovative assets for the detection of infectious diseases and bio-terrorism threat agents.
Mike has a Master's in Biotechnology Enterprise and Entrepreneurship from the Johns Hopkins University and a BS in biology from Radford University.